|
审核状态: Project audit state: |
通过审核 Successful |
|
注册号: Registration number: |
ChiCTR2600123333 |
|
最近更新日期: Date of Last Refreshed on: |
2026-04-24 15:57:28 |
|
注册时间: Date of Registration: |
2026-04-24 00:00:00 |
|
注册号状态: |
预注册 |
|
Registration Status: |
Prospective registration |
|
注册题目: |
敌草快中毒预后及影响因素分析 |
|
Public title: |
Study of prognostic factors of diquat poisoning |
|
注册题目简写: |
|
|
English Acronym: |
|
|
研究课题的正式科学名称: |
基于白细胞计数与临床指标的敌草快中毒床旁风险分层体系的构建与基层推广应用研究 |
|
Scientific title: |
Development and Primary Care Implementation of a Bedside Risk Stratification Tool for Acute Diquat Poisoning Based on White Blood Cell Count and Clinical Indicators |
|
研究课题代号(代码): Study subject ID: |
|
|
在二级注册机构或其它机构的注册号: The registration number of the Partner Registry or other register: |
|
申请注册联系人: |
张晔 |
研究负责人: |
张晔 |
|
Applicant: |
Ye Zhang |
Study leader: |
Ye Zhang |
|
申请注册联系人电话: Applicant telephone: |
+86 10 69843251 |
研究负责人电话:
Study leader's |
+86 10 69824234 |
|
申请注册联系人传真 : Applicant Fax: |
研究负责人传真: Study leader's fax: |
||
|
申请注册联系人电子邮件: Applicant E-mail: |
zhangye422208@163.com |
研究负责人电子邮件: Study leader's E-mail: |
zhangye422208@163.com |
|
申请单位网址(自愿提供): Applicant website(voluntary supply): |
研究负责人网址(自愿提供): Study leader's website(voluntary supply): |
||
|
申请注册联系人通讯地址: |
北京市门头沟区河滩桥东街10号 |
研究负责人通讯地址: |
北京市门头沟区医院河滩桥东街10号 |
|
Applicant address: |
No.10, Hetanqiao East Street, Mentougou District, Beijing |
Study leader's address: |
No.10, Hetanqiao East Street, Mentougou District, Beijing |
|
申请注册联系人邮政编码: Applicant postcode: |
研究负责人邮政编码: Study leader's postcode: |
||
|
申请人所在单位: |
北京市门头沟区医院 |
||
|
Applicant's institution: |
Beijing Mentougou District Hospital |
||
|
研究负责人所在单位: |
北京市门头沟区医院 |
||
|
Affiliation of the Leader: |
Beijing Mentougou District Hospital |
||
|
是否获伦理委员会批准: |
是 |
||
|
Approved by ethic committee: |
Yes |
||
|
伦理委员会批件文号: Approved No. of ethic committee: |
2026-QYYKY-A03 |
伦理委员会批件附件: Approved file of Ethical Committee: |
查看附件View |
|
批准本研究的伦理委员会名称: |
北京市门头沟区医院医学伦理委员会 |
||
|
Name of the ethic committee: |
Ethics Committee Of Beijing Mentougou District Hospital |
||
|
伦理委员会批准日期: Date of approved by ethic committee: |
2026-04-03 00:00:00 | ||
|
伦理委员会联系人: |
邓伟 |
||
|
Contact Name of the ethic committee: |
DengWei |
||
|
伦理委员会联系地址: |
北京市门头沟区医院河滩桥东街10号 |
||
|
Contact Address of the ethic committee: |
No.10, Hetanqiao East Street, Mentougou District, Beijing |
||
|
伦理委员会联系人电话: Contact phone of the ethic committee: |
+86 10 69820215 |
伦理委员会联系人邮箱: Contact email of the ethic committee: |
496426054@qq.com |
|
研究实施负责(组长)单位: |
北京市门头沟区医院 |
||||||||||||||||||||||
|
Primary sponsor: |
Beijing Mentougou District Hospital |
||||||||||||||||||||||
|
研究实施负责(组长)单位地址: |
北京市门头沟区医院河滩桥东街10号 |
||||||||||||||||||||||
|
Primary sponsor's address: |
No.10, Hetanqiao East Street, Mentougou District, Beijing |
||||||||||||||||||||||
|
试验主办单位(项目批准或申办者): Secondary sponsor: |
|
||||||||||||||||||||||
|
经费或物资来源: |
首都卫生发展科研专项项目 |
||||||||||||||||||||||
|
Source(s) of funding: |
Capital’s Funds for Health Improvement and Research |
||||||||||||||||||||||
|
研究疾病: |
急性敌草快中毒 |
||||||||||||||||||||||
|
Target disease: |
acute diquat poisoning |
||||||||||||||||||||||
|
研究疾病代码: |
|
||||||||||||||||||||||
|
Target disease code: |
|
||||||||||||||||||||||
|
研究类型: |
观察性研究 |
||||||||||||||||||||||
|
Study type: |
Observational study |
||||||||||||||||||||||
|
研究所处阶段: |
其它 | ||||||||||||||||||||||
|
Study phase: |
N/A |
||||||||||||||||||||||
|
研究设计: |
连续入组 |
||||||||||||||||||||||
|
Study design: |
Sequential |
||||||||||||||||||||||
|
研究目的: |
基于前期构建的五因素列线图模型,通过多中心双向队列研究进行外部验证与优化,最终建立一套完全基于常规临床指标、适用于基层医疗机构的急性敌草快中毒风险分层标准化工具及临床实践路径。 |
||||||||||||||||||||||
|
Objectives of Study: |
Based on the previously established five-factor linear model, an external validation and optimization were conducted through a multicenter cohort study. Eventually, a set of standardized tools and clinical practice pathways for risk stratification of acute diquat poisoning, fully based on routine clinical indicators and applicable to primary medical institutions, was established. |
||||||||||||||||||||||
|
药物成份或治疗方案详述: |
|
||||||||||||||||||||||
|
Description for medicine or protocol of treatment in detail: |
|
||||||||||||||||||||||
|
纳入标准: |
1.年龄大于或等于14岁; |
||||||||||||||||||||||
|
Inclusion criteria |
1. Age greater than or equal to 14 years old; 2. There is a clear history of oral or contact exposure to dicamba, accompanied by corresponding acute poisoning clinical symptoms; 3. The time from poisoning to the first visit was less than 24 hours. 4. The patient or their legal representative signs the informed consent form. |
||||||||||||||||||||||
|
排除标准: |
1.合并其他明确毒物(如百草枯、有机磷、氨基甲酸酯类等)混合中毒者; |
||||||||||||||||||||||
|
Exclusion criteria: |
1. Combine those who have suffered from mixed poisoning by other definite toxins (such as paraquat, organophosphorus, carbamate, etc.); 2. Comorbid with severe underlying diseases at end-stage: NYHA cardiac function grade IV, Gold COPD grade IV, eGFR < 30 mL/min/1.73m2 (CKD stage 4-5), Child-Pugh C grade liver cirrhosis, advanced malignant tumors, etc. 3. Pregnant or lactating women; 4. Those who were discharged from the hospital automatically within 24 hours after admission or gave up treatment, resulting in incomplete collection of the main observation indicators; 5. The clinical data is severely lacking, making it impossible to collect the key variables. |
||||||||||||||||||||||
|
研究实施时间: Study execute time: |
从 From 2016-01-01 00:00:00至 To 2029-12-31 00:00:00 |
征募观察对象时间: Recruiting time: |
从 From 2026-05-01 00:00:00 至 To 2029-12-31 00:00:00 |
|
干预措施: Interventions: |
|
|
研究实施地点: Countries of recruitment and research settings: |
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
测量指标: Outcomes: |
|
|
采集人体标本:
Collecting sample(s)
|
|
|
征募研究对象情况: Recruiting status: |
尚未开始 Not yet recruiting |
年龄范围: Participant age: |
|
||||||
|
性别: |
男女均可 |
Gender: |
Both |
||||||
|
随机方法(请说明由何人用什么方法产生随机序列): |
无 |
||||||||
|
Randomization Procedure (please state who generates the random number sequence and by what method): |
None |
||||||||
|
是否公开试验完成后的统计结果: Calculated Results after the Study Completed public access: |
不公开/Private |
|
盲法: |
无 |
|
Blinding: |
None |
|
是否共享原始数据: IPD sharing |
否No |
|
共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址): |
无 |
|
The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url): |
None |
|
数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC: |
电子采集和管理系统 |
|
Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture: |
Electronic Collection and Management System |
|
数据与安全监察委员会: Data and Safety Monitoring Committee: |
有/Yes |